This HTML5 document contains 55 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n7http://linked.opendata.cz/resource/domain/vavai/projekt/
n10http://linked.opendata.cz/resource/domain/vavai/subjekt/
n9http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
n13http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n17http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00209805%3A_____%2F13%3A%230000428%21RIV14-GA0-00209805/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n20http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n5http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00209805%3A_____%2F13%3A%230000428%21RIV14-GA0-00209805
rdf:type
skos:Concept n9:Vysledek
rdfs:seeAlso
http://dx.doi.org/10.1155/2013/761537
dcterms:description
Endocrine resistance is a significant problem in breast cancer treatment. Thus identification and validation of novel resistance determinants is important to improve treatment efficacy and patient outcome. In our work, AGR2 expression was determined by qRT-PCR in Tru-Cut needle biopsies from tamoxifen-treated postmenopausal breast cancer patients. Our results showed inversed association of AGR2 mRNA levels with primary treatment response (P = 0.0011) and progression-free survival (P = 0.0366) in 61 ER-positive breast carcinomas. As shown by our experimental and clinical evaluations, elevated AGR2 expression predicts decreased efficacy of tamoxifen treatment. From this perspective, AGR2 is a potential predictive biomarker enabling selection of an optimal algorithm for adjuvant hormonal therapy in postmenopausal ER-positive breast cancer patients. Endocrine resistance is a significant problem in breast cancer treatment. Thus identification and validation of novel resistance determinants is important to improve treatment efficacy and patient outcome. In our work, AGR2 expression was determined by qRT-PCR in Tru-Cut needle biopsies from tamoxifen-treated postmenopausal breast cancer patients. Our results showed inversed association of AGR2 mRNA levels with primary treatment response (P = 0.0011) and progression-free survival (P = 0.0366) in 61 ER-positive breast carcinomas. As shown by our experimental and clinical evaluations, elevated AGR2 expression predicts decreased efficacy of tamoxifen treatment. From this perspective, AGR2 is a potential predictive biomarker enabling selection of an optimal algorithm for adjuvant hormonal therapy in postmenopausal ER-positive breast cancer patients.
dcterms:title
AGR2 predicts tamoxifen resistance in postmenopausal breast cancer patients AGR2 predicts tamoxifen resistance in postmenopausal breast cancer patients
skos:prefLabel
AGR2 predicts tamoxifen resistance in postmenopausal breast cancer patients AGR2 predicts tamoxifen resistance in postmenopausal breast cancer patients
skos:notation
RIV/00209805:_____/13:#0000428!RIV14-GA0-00209805
n9:predkladatel
n10:ico%3A00209805
n4:aktivita
n16:I n16:P
n4:aktivity
I, P(ED2.1.00/03.0101), P(GA13-00956S), P(NT13794)
n4:cisloPeriodika
4
n4:dodaniDat
n5:2014
n4:domaciTvurceVysledku
n8:6760074 n8:1330586 n8:3989151 n8:9637419 n8:7947429
n4:druhVysledku
n18:J
n4:duvernostUdaju
n14:S
n4:entitaPredkladatele
n17:predkladatel
n4:idSjednocenehoVysledku
59777
n4:idVysledku
RIV/00209805:_____/13:#0000428
n4:jazykVysledku
n20:eng
n4:klicovaSlova
protein anterior gradient-2; estrogen-receptor; human homolog; expression; pathway; antigen; gene
n4:klicoveSlovo
n6:expression n6:human%20homolog n6:estrogen-receptor n6:antigen n6:protein%20anterior%20gradient-2 n6:gene n6:pathway
n4:kodStatuVydavatele
US - Spojené státy americké
n4:kontrolniKodProRIV
[917C7AC3CD44]
n4:nazevZdroje
Disease Markers
n4:obor
n15:FD
n4:pocetDomacichTvurcuVysledku
5
n4:pocetTvurcuVysledku
5
n4:projekt
n7:ED2.1.00%2F03.0101 n7:NT13794 n7:GA13-00956S
n4:rokUplatneniVysledku
n5:2013
n4:svazekPeriodika
35
n4:tvurceVysledku
Vojtěšek, Bořivoj Brychtová, Veronika Fabian, Pavel Svoboda, Marek Hrstka, Roman
n4:wos
000324981400001
s:issn
0278-0240
s:numberOfPages
6
n13:doi
10.1155/2013/761537